AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer

AstraZeneca Plc AZN and Daiichi Sankyo DSNKY announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki).
The trial included HER2-positive metastatic and/or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma patients previously treated with a trastuzumab-containing regimen.
Detailed results provided a clinically meaningful and durable tumor response and were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.
In the primary analysis of the DESTINY-Gastric02 trial, Enhertu (6.4 mg/kg) demonstrated a confirmed overall response rate (ORR) of 38% as assessed by independent central review (ICR).
Three (3.8%) complete responses (CR) and 27 (34.2%) partial responses (PR) were observed in patients treated with Enhertu.
After a median follow-up of 5.7 months, the median duration of response (DoR) of Enhertu was 8.1 months.
The median progression-free survival (PFS) was 5.5 months.
An exploratory endpoint of confirmed disease control rate (DCR) of 81% was seen.
The overall safety profile of Enhertu in DESTINY-Gastric02 was consistent with that seen in DESTINY-Gastric01.
Price Action: AZN stock is down 1.86% at $55.55 during the market session on the last check Friday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).